The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective. by Saynor, ZL et al.
  
Case Report 
 
The Effect of Ivacaftor in Adolescents with Cystic Fibrosis (G551D mutation): An 
Exercise Physiology Perspective 
 
Authors: Zoe Louise Saynor (MSc)
a,b
, Dr. Alan Robert Barker (PhD)
a
, Dr. Patrick John 
Oades (FRCPCH)
b
, Prof. Craig Anthony Williams (PhD)
a*
 
 
 
Running Title: Cardiopulmonary Exercise Testing in CF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conflict of Interest Statement: The authors declare no conflicts of interest.  
 
Grant support: No grant support was required for this study.  
 
 
Author affiliations: 
a Children’s Health and Exercise Research Centre, Sport and Health 
Sciences, University of Exeter, Exeter, Devon, UK; 
b 
Royal Devon and Exeter NHS 
Foundation Trust Hospital, Exeter, Devon, UK.  
 
Correspondence: Craig A. Williams, Children’s Health and Exercise Research Centre, Sport 
and Health Sciences, University of Exeter, St. Luke’s Campus, Heavitree Road, Exeter, EX1 
2LU, UK. Email: c.a.williams@exeter.ac.uk 
 
 
 
 
 
 
 
 Acknowledgements 
The authors thank the patients who kindly volunteered their time to be involved in this study. 
They also extend their gratitude to the Cystic Fibrosis care team at the Royal Devon and 
Exeter Hospital for their continued support.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT 
 
Purpose: The purpose of this report was to evaluate the influence of 12 weeks of ivacaftor 
treatment on the aerobic function of 2 teenage patients with cystic fibrosis (CF; 
ΔF508/G551D) using a maximal cardiopulmonary exercise test.  
 
Summary of Key Points: One patient, with relatively mild disease, demonstrated no 
clinically meaningful changes in maximal oxygen uptake (V̇O2max). However, in the second 
case, with more established lung disease on imaging, V̇O2max improved by approximately 
30%, an improvement out of proportion with early lung function changes. This improvement 
resulted from increased muscle oxygen delivery and extraction.  
 
Statement of Conclusions: Cardiopulmonary exercise testing can monitor the extent and 
cause(s) of change following interventions such as ivacaftor, with the potential to identify 
functional changes independent from spirometry indices.   
 
Recommendations for Clinical Practice: Cardiopulmonary exercise testing represents an 
important and comprehensive clinical assessment tool, and its use as an outcome measure in 
the functional assessment of patients with CF is encouraged.  
 
 
Key words: adolescent, cardiopulmonary exercise test, cystic fibrosis, drug therapy, 
exercise/physiology.  
 
 
 INTRODUCTION 
Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein. Traditional therapies focus on 
alleviating manifestations secondary to CFTR dysfunction. A new oral treatment (ivacaftor , 
Vertex Pharmaceuticals, Boston, Massachusetts) has been licenced specifically for those with 
the G551D-CFTR mutation. Ivacaftor, a CFTR “potentiator”, increases the open time of 
activated CFTR at the cell surface, restoring chloride-transport activity of the G551D-CFTR 
protein
1
.  
To date, sustained improvements in quality of life, incidence of pulmonary 
exacerbations, respiratory symptoms, pulmonary function, weight, and biomarkers of CFTR 
activity (sweat chloride and nasal potential difference) have been reported following 
treatment with ivacaftor in patients that are heterozygous for the G551D mutation with mild-
to-moderately impaired lung function, without substantial adverse effects
2,3,4,5
. More recently, 
administration of ivacaftor has also revealed clinical improvements in severely ill patients
6
 
and a G551D homozygote
7
.  
 Although common clinical assessments such as spirometry and body weight provide 
key endpoints for the evaluation of new CF treatments, their sensitivity to detect change in 
early disease has been questioned
8
. Furthermore, measurements of lung function cannot 
accurately predict patients’ exercise capacity. Aerobic fitness (maximal oxygen uptake, 
V̇O2max) is of particular clinical importance in patients with CF given its association with 
longevity
9,10
, quality of life
11
 and reduced risk of hospitalization
12
. However, exercise testing 
as an outcome in both physical therapy practice and therapeutic trials remains in its infancy
13
. 
Understanding how the clinical alterations evident following pharmacological or physical 
therapy treatment translate to patients’ physical function is important.   
  Only 1 previous study investigating the effects of ivacaftor has incorporated an 
exercise testing measure
7
, documenting a 292% (+410 m) improvement from baseline in the 
distance achieved during the 6-minute walk test in a female adult (G551D homozygote) 
following 12 months of treatment. Although tests such as this are common practice within 
physical therapy for individuals with CF, a number of methodological issues accompany 
these crude tests, which must be considered when used in this context. First, these tests are 
often subjective and submaximal in nature and fail to quantify physiologically a maximal 
effort. Second, the derived parameters are limited to heart rate and arterial oxygen saturation, 
which are often not presented and do not provide physiological data to support the 
mechanism(s) responsible for any observed change.  
Maximal cardiopulmonary exercise testing (CPET), incorporating measurement of 
gas exchange, provides the most precise measurement of aerobic fitness. Much of the value 
of CPET resides in its capacity to describe the integrated function of the pulmonary, 
cardiovascular and muscular systems during exercise. Moreover, in addition to V̇O2max, 
additional key parameters of aerobic exercise function can also be obtained, such as the O2 
cost of exercise (exercise efficiency)
14
. In response to the European CF Society (ECFS) 
Clinical Trials Network Standardization Committee’s call to assess the validity, 
reproducibility and feasibility of outcome measures to be used in CF, a valid protocol for use 
with young patients with CF was recently presented
15
. Furthermore, the typical error 
associated with the derived outcome measures has since been presented
16
, enabling 
meaningful change from therapeutic or physical therapy interventions to now be ascertained. 
However, to our knowledge there are no reports of effect of ivacaftor on patients’ aerobic 
fitness assessed using the reference standard CPET.  
The purpose of this report was to provide novel data from CPET in 2 teenage patients 
with cystic fibrosis (∆F508/G551D) treated with ivacaftor to demonstrate (1) the effects of 
 ivacaftor on aerobic function and (2) the possible factor(s) modulating this response. By 
answering these questions, the report will provide novel data on the utility and feasibility of 
CPET as a clinical outcome measure.  
 
CASE DESCRIPTION 
Participants 
Case A: A 14 y old female climbing enthusiast had presented with neonatal meconium ileus 
requiring bowel resection. She suffered a complicated clinical course, with early 
Pseudomonal and then Stenotrophomonal respiratory infections, allergic bronchopulmonary 
aspergillosis, and more recently Mycobacterium abscessus infection that could not be 
eradicated. Despite preserved lung function (forced expiratory volume in 1 second (FEV1)) 
92% predicted), thoracic high-resolution computed tomography (HRCT) detailed extensive 
bronchiectasis and consolidation in right middle and lingual lobes (Fig. 1A). Body mass 
index (BMI) was 20.3 kg·m
2
 (> 50
th
 centile). Sweat chloride measured 104 mmol·L
-1
 
pretreatment. Routine maintenance medications included the following: pancrelipase (10 000 
and 40 000 in various combinations with meals and snacks), vitamin E (200 units alternate 
days), vitamin A and D gel (1 daily), ursodeoxycholic acid (450 mg twice daily), 
polyethylene glycol solution (1 sachet daily), azithromycin (500 mg daily), doxycycline (100 
mg once daily), meropenem (nebuliser 250 mg twice daily), dornase alpha (nebulizer 2.5 mg 
once daily), hypertonic saline (7% nebulized [4 ml] once or twice daily with physical 
therapy), beclomethasone (200 μg twice daily via spacer), salbutamol (2-4 puffs when 
required for wheezing), and amphotericin (nebulized 20 mg alternate days, nonliposomal 
formulation).    
 
 Case B: An active 16-year-old male presented at the age of 16 months with recurrent 
respiratory infections and failure to thrive. He has suffered recurrent Pseudomonal infections 
from an early age but has remained well with aggressive treatments (FEV1 108% predicted). 
Thoracic HRCT showed widespread bronchiectatic changes but without significant 
consolidation (Fig. 1B). BMI was 19.7 kg·m
2
 (50
th
 centile). Sweat chloride measured 107 
mmol·L
-1
 pretreatment. Routine maintenance medications included the following: 
pancrelipase (10 000 and 40 000 in various combinations with meals and snacks), vitamin A 
and D gel caps (3 daily), vitamin E (200 units daily), vitamin K (10 mg daily), Fortisip 
Compact nutritional supplement (with Creon 2 daily), colomycin (nebulized 2 mega units 
mixed with gentamicin 80 mg twice daily), dornase alpha (nebulized 2.5 mg once daily), 
flucloxacillin (500 mg twice daily). 
 
Description of Intervention 
The main goal of this intervention was to assess the influence of orally administered ivacaftor 
treatment (150 mg 12 hourly) on CPET-derived measures of aerobic function in 2 young 
patients with CF in conjunction with common clinical outcome measures. To monitor the 
effects of treatment, the 2 teenage patients, both compound heterozygotes (G551D/ΔF508), 
underwent routine clinical assessments for a 20-week duration.  
In addition to this, CPET was performed before and after (6 and 12 weeks) initiating 
orally administered ivacaftor treatment to assess whether any change in aerobic function was 
evident and, if so, the physiological factor(s) responsible for this. These time points for 
reassessment were implemented to enable comparison of intervention-induced changes with 
the typical error of the CPET measurements established in this patient population over this 
time period to identify clinically meaningful changes
16
. The patients continued their normal 
maintenance medications as required and continued with their typical physical activity and 
 nutritional intake patterns. Additional measurements of central (O2 delivery) and peripheral 
(O2 extraction/ utilization) factors that can influence V̇O2max were also obtained to understand 
the mechanism(s) responsible for any change.  
  
Maximal Cardiopulmonary Exercise Testing.  
Participants were instructed to arrive at the exercise laboratory in a rested state, 2 
hours or more postprandial and having refrained from caffeine for 2 hours or more. 
Following thorough familiarization with the equipment and requirements of the visit, a 
maximal CPET was performed on a cycle ergometer [Lode Excalibur or Lode Corival, 
Groningen, The Netherlands]. A single-session protocol, encompassing a ramp incremental 
test (10-25 W·min
-1
) and a supramaximal (110% peak power output [PPO]) verification 
phase (Smax) that has been validated in this patient population
15
 was used. Following a 3-
minute warm-up (20 W cycling), the incremental ramp test was completed until exhaustion 
whilst pedalling between 70 to 80 revolutions per minute. Exhaustion was defined as a drop 
in pedal speed of more than 10 revolutions per minute for 5 consecutive seconds, despite 
strong verbal encouragement. Participants then completed 5-minute active recovery (20 W 
cycling) and 10-minute passive seated recovery before completing the Smax verification test. 
Smax involved a 3-minute warm-up (20 W cycling), an exhaustive “step” transition to a 
constant work rate equivalent to 110% PPO from the ramp test, followed by 5-minutes active 
recovery (20 W cycling).  
 
Assessment Methods 
Anthropometry and pulmonary function. Body mass (Seca 220; Vogel & Halke, 
Hamburg, Germany) and stature (Seca 220; Vogel & Halke, Hamburg, Germany) were 
measured to the nearest 0.01 kg and 0.01 m, respectively. FEV1 and forced vital capacity 
 (FVC) were assessed using spirometry (MicroMedical MicroLoop 3535). The best of three 
consistent (< 5% variability) exhalations was documented and expressed as a percentage of 
predicted reference data.
[17] 
 
Pulmonary gas analysis. Prior to each exercise test, a metabolic cart (Metalyzer 3B Cortex, 
Biophysik, Leipzig, Germany) was calibrated using gases of known concentration, and the 
turbine volume transducer using a 3 L calibration syringe (Hans Rudolph, Kansas City, MO). 
Breath-by-breath pulmonary gas exchange and ventilation were measured and averaged to 
15-second time bins.  The highest 15-second stationary average V̇O2 from the combined ramp 
and supramaximal exercise tests (described later) was taken to represent V̇O2max, a safe and 
appropriate V̇O2max verification criterion in this population.
[15]
 The primary outcome measure, 
given its clinical important in CF, was V̇O2max. However, additional submaximal parameters 
of aerobic fitness were also derived. The lactate threshold was noninvasively identified using 
the gas exchange threshold (GET)
[18]
 and confirmed through visual inspection of the 
ventilatory equivalents for V̇O2 and V̇CO2. The V̇O2 “gain” (ΔV̇O2/ΔWR), a measure of 
exercise efficiency, was determined by regression of the “linear” portion of the V̇O2 response 
against power output.  
 
Additional mechanistic measures: Thoracic bioelectrical impedance (PhysioFlow, PF-05, 
Manatec Biomedical, Paris, France), which has been validated in CF,
[19]
 was used to 
noninvasively measure beat-by-beat heart rate (HR), stroke volume (SV) and cardiac output 
(?̇?), which was subsequently averaged to 15-second time intervals. Arterial-venous O2 
context difference (C(a-?̅?)O2), a measure of O2 extraction, was estimated via rearrangement of 
the Fick equation:  
 (C(a-?̅?)O2)  =  
V̇O2
?̇?
 
Arterial O2 saturation at the fingertip (SpO2) was measured on a beat-by-beat basis via pulse 
oximetry (NONIN, Avant 4000, NONIN Medical Inc., USA). Subjective ratings of perceived 
exertion (RPE) and dyspnea (RPD) were recorded upon exhaustion using methodology 
described elsewhere.
[15,16]
 All procedures and protocol were approved by the institutional 
ethics committee and informed parental consent and participant assent were obtained prior to 
the commencement of the study.  
 
OUTCOMES 
The 2 patients’ clinical and exercise characteristics at baseline and in response to 12 weeks of 
treatment with ivacaftor are presented in Table 1. Figure 2 presents the percentage change in 
BMI, FEV1 and V̇O2max during 12 weeks of treatment. BMI and FEV1 were then monitored 
during follow-up up to week 20. The magnitude of change in these measurements is 
presented in relation to the established typical error of measurement using these procedures 
over a 4-6 week period
16
. All exercise testing was well tolerated with no adverse events, and 
all tests satisfied the criteria for the provision of a maximal effort. However, case B reported 
to his 12 week CPET feeling fatigued.  
 
Case A 
This patient experienced 2 successive upper respiratory tract infections (URTI) (weeks 3 and 
10) during treatment. Despite this, her lung function and body weight were maintained when 
she would typically deteriorate. Following the first 6 weeks of treatment, her weight had 
increased from 48.5 kg to 50.5 kg, while predicted FEV1 increased from 92% to 96%. A fall 
in her sweat chloride (104 to 21 mmol·L
-1
) was noted at this time point. Following 6 weeks of 
treatment her body mass normalized V̇O2max had increased by 6.4% from baseline, which was 
 not considered clinically a meaningful improvement since it resides within the typical error of 
this measurement
16
. End-exercise SpO2 upon exhaustion increased from 92% to 96%. 
Because of a combination of leg fatigue (9 out of 10) and dyspnea (rating of 7 out of 10) 
CPET was terminated.  
 At the 12-week assessment, subjectively she reported feeling better and more 
“energetic” and was slightly more productive with airway clearance physiotherapy. Her 
FEV1% and weight showed moderate though convincing increases (+4.7% relative and +1.7 
kg, respectively). A small increase in sweat chloride (21 to 35 mmol·L
-1
) was evident. 
Although there was minimal influence upon PPO, subjective ratings of exertion and dyspnea 
or the additional submaximal parameters of aerobic fitness (GET and V̇O2 gain) at this time 
point, her body mass normalized V̇O2max had increased by 30.3% from pretreatment baseline. 
This substantial increase was deemed clinically meaningful since the change over this 6 week 
period exceeded the typical error (13.3%) of measurement established over this duration
16]
. 
Furthermore, end-exercise SpO2 had improved to 98% from 95% pretreatment. By this point, 
her PPO had also increased by 9.0% (12 W) and her rating of dyspnea had improved from 7 
to 5. Little change was detected in the submaximal parameters of aerobic fitness.  
 Of the factors which can affect patient A’s V̇O2max, a change was observed in both 
central (O2 delivery) and peripheral (O2 extraction) indices. With regard to O2 delivery, a 
slight reduction in HR was evident at weeks 6 and 12 (205 beats∙min-1 to 202 beats∙min-1 at 
both tests). However, since SV was increased at both time points [52 mL∙beat-1 to 56 (+7%) 
and 60 (+15%) mL∙beat-1], ?̇? was improved as a consequence [10.6 L·min-1 to 10.8 and 11.6 
L·min
-1
 (+2% and +9%, respectively)]. Arterial O2 desaturation upon exhaustion was also 
reduced during the 12 weeks of treatment, with SpO2 rising from 92% to 96% and 98% at 
weeks 6 and 12, respectively.  Estimated O2 extraction (C(a-?̅?)O2) was also increased at both 
week 6 [+1 mL·min
-1
·100mL (+ 8%) and week 12 [+3 mL·min
-1
·100mL (+ 23%)]. This 
 change in physiological function detected through CPET following 12 weeks of treatment 
preceded the later rise detected in FEV1 (+19% from baseline) following 20 weeks (Figure 2). 
Her weight also increased further to 52.4 kg (+3.9 kg from baseline) at this stage.  
 
Case B 
This patient was clinically well throughout treatment and body weight and lung function 
remained stable. Following 6 weeks of treatment, his weight remained stable at 58.3 kg while 
lung function (FEV1) improved from 108% to 112% predicted. A notable fall in sweat 
chloride (107 to 58 mmol·L
-1
) was also evident in this patient at this time point. A modest 
improvement in his body mass normalized V̇O2max from baseline was evident (+3.4%); 
however, this was not considered clinical meaningful. End-exercise SpO2 was unchanged at 
96% and CPET was terminated because of both leg fatigue (RPE of 9) and dyspnea (RPD of 
7). 
 Following 12 weeks of treatment, he reported feeling clinically well; however he was 
tired because of heavy school and football workloads over the preceding weeks. In a patient 
who has difficulty maintaining weight, he had gained 0.5 kg by week 12. FEV1 had also 
increased from 108% predicted at baseline to 120% predicted and sweat chloride 
concentration has reduced further to 43 mmol∙L-1. Although PPO increased by 9% from 
baseline (20 W) and SpO2 at exhaustion had improved from 96% to 98%, his body mass 
normalized V̇O2max was marginally reduced (-5.1% from baseline) as were the submaximal 
indicators of aerobic fitness. However, this should not be considered a true impairment of 
aerobic function as it is within the typical error of these measurements
16
. While his perceived 
dyspnea upon exhaustion was higher (7-9), RPE remained stable at 9. 
Although modest improvement was observed in his systemic O2 delivery (cardiac 
output and SpO2), this appeared to fluctuate around baseline. Maximal ?̇? was 19.0 L·min
-1
 at 
 baseline and then 15.5 and 18.2 L·min
-1
 following 6 and 12 weeks of treatment, respectively. 
HR and SV remained relatively stable at week 6 (-3 beats·min
-1
 and +5 mL·beat
-1
, 
respectively). However, at 12 weeks his SV was increased to 104 mL·beat
-1
 and maximal HR 
was substantially lower at 175 beats·min
-1
, meaning ?̇? was not particularly influenced. 
Furthermore, following increased extraction at 6 weeks (+3 mL·min
-1
·100mL), this was near 
baseline by week 12 (-0.2 mL·min
-1
·100mL). No clinically significant change in SpO2 was 
observed. Continued clinical monitoring to week 20 then revealed a steady increase in weight 
to gain 3.2 kg from baseline and increase the relative change from baseline in FEV1% 
predicted to 6.7%.  
 
DISCUSSION 
The aim of this case report was to describe the effects of orally administered ivacaftor on the 
aerobic exercise function and clinical profile of 2 teenage patients with CF (A, 14 y old 
female; B, 16 y old male) who were heterozygous for the G551D mutation. Furthermore, this 
report aimed to demonstrate the utility of CPET as a clinical outcome measure. Following 12 
weeks of treatment with ivacaftor, both patients showed substantial improvements in sweat 
chloride. Despite patient A experiencing 2 successive URTIs, lung function and body weight 
were maintained when she would typically deteriorate. Patient B was clinically well 
throughout treatment, with his body weight and lung function stable throughout. Following 
12 weeks of treatment, no meaningful change was observed in V̇O2max in patient B. In patient 
A, however, V̇O2max increased by 30.3%, which should be considered clinically meaningful 
because it is 20% greater than the 4 to 6 week typical error associated with this measurement. 
This improvement resulted from both enhanced muscle O2 delivery and muscle O2 extraction.
 There could be numerous explanations for the varied response observed between 
these patients. Firstly, at outset, both patients presented with mildly impaired lung function. 
 However, Case A’s lung function was a little lower,  evidence of active underlying infection 
with M. Abscessus was present and thoracic HRCT identified more severe lung damage with 
patchy parenchymal inflammatory changes. Although established lung damage cannot 
directly be rectified, this patient may well have had more to gain from this new, 
transformational treatment. In an earlier ivacaftor clinical trial cohort
3
, improvements in 
sweat chloride and FEV1 were seen to plateau after 2 weeks. Because case B’s lung function 
at baseline was higher than the patients in this initial study by Ramsey et al.
3
, this may 
explain why a plateau was observed in his response.  
 Conceivably, an individual ceiling effect for V̇O2max improvements may exist, 
whereby relatively fit patients have less to gain in the absence of exercise training, and that 
case B’s original fitness status resided around this threshold. As such, case A’s V̇O2max 
normalized to body mass was lower than case B at baseline, of which gender difference may 
be a factor. An impact of overreaching or chronic fatigue in case B also cannot be excluded. 
Although a higher PPO was documented, this patient reported to the exercise laboratory for 
his week 12 CPET feeling tired, due to school and football workloads. His lower maximal 
heart rate (~20 beats·min
-1
) compared with his previous CPETs may support this. 
Interestingly, this reduced response has previously been observed in this patient when he 
previously performed 2 CPETs over a short-term period. This stresses the importance of 
CPET standardization when interpreting “true” physiological changes in results. Although 
measures of O2 delivery, extraction and minimum SpO2 in this patient all fluctuated around 
baseline, without meaningful change, SV was elevated following 12 weeks. However, given 
that maximal HR was lower, his resulting ?̇? was not increased.   
 To our knowledge, the only existing evidence of ivacaftor’s effect upon aerobic 
fitness was demonstrated in a 19-year-old G551D homozygote with poor lung function using 
the 6-minute walk test [292% (+ 410 m) improvement from baseline)
7
. However, in contrast 
 to this study, the shuttle walk assessment by Harrison et al.
7
 was undertaken following 12 
months of treatment. However, although only presented graphically, the authors’ figure 
indicate that exercise testing was also performed at approximately 2 and 10 weeks. 
Interestingly, the majority of the patient’s improvement in aerobic fitness occurred within the 
time period spanning these 2 time points (~ +225 m (week 2) and ~ +310 m (week 10) from 
baseline, respectively). Only further longitudinal study would confirm the inter-patient 
variability observed within the present case report and determine whether ivacaftor could 
sustain patients’ aerobic fitness following initial improvements. However, data from the 
Harrison et al.
7
 study are promising, presenting a modest but steady improvement from 
approximately 10 weeks to 52 weeks of treatment. Of additional interest is the relatively 
fixed status of the submaximal indices of aerobic function (GET% and V̇O2 gain) in contrast 
to the acute improvement in maximal oxygen uptake. Whether these parameters respond over 
a longer duration warrants further exploration.  
 The data from this study are clinically useful for a number of reasons. Firstly, they are 
novel data regarding the mechanisms by which ivacaftor may enhance patients’ physiological 
function during exercise. The magnitude of change in this patient was particularly impressive 
given that 1) she was in a state of URTI during the majority of her treatment, 2) 
improvements cannot simply be attributable to a learning effect or initial submaximal effort, 
because both patients were thoroughly familiarized with the protocol that encompasses a 
verification phase to confirm “true” V̇O2max
15
; and 3) no exercise training intervention was 
undertaken outside the patients’ typical physical activity routine. 
 Sparse data exists concerning the magnitude of change in V̇O2max of young patients 
with CF following pharmacological or exercise interventions. To date, only 1 previous study 
has demonstrated a meaningful improvement in V̇O2max in young patients with CF and this 
was following an intense 6-week period of exercise training. Hulzebos et al.
20
 reported a 
 “meaningful” improvement (19%), following a high-intensity cycling exercise training 
programme. This training intervention resulted in an indication of enhanced O2 delivery to 
the active muscle tissue, evidenced by the O2 pulse. It was suggested that O2 extraction was 
also influenced; however, only data for the V̇O2 gain was presented, which provides a 
measure of submaximal O2 consumption and exercise efficiency.   
 An additional important purpose of the present report was to demonstrate the utility of 
CPET to make inferences regarding therapeutic interventions or disease-related changes. 
Although case A reported feeling better and more “energetic” at week 12, no clinical 
improvement was detected using standard spirometric indices until week 20. However, CPET 
did document substantial improvement in her physiological function. The fact that her V̇O2max 
improvement was out of proportion with early lung function changes, although the latter did 
pick up during extended follow-up, demonstrated the capacity of this integrated testing to 
detected subtle changes in patients that are relatively well earlier than common clinical 
outcomes. Furthermore, although more common clinical exercise tests are often cost-effective 
and easily conducted, a CPET can provide a wealth of mechanistic information that cannot be 
derived from standard clinical assessments or crude exercise tests such as shuttle walk or step 
protocols. In addition, although such tests can be used to estimate V̇O2max, they are likely to 
underestimate aerobic fitness and cannot truly verify a maximal effort. Owing to its merits, 
the ECFS Exercise Working Group recently promoted CPET as the exercise testing method 
of choice where possible for this patient group. 
 Aerobic fitness is an important clinical parameter in CF and should become an 
important outcome within the physical therapy assessment of patients. Although the present 
report focused on the utility of CPET to assess the response to ivacaftor, more common 
practices such as intravenous antibiotics (IVABs) and physical therapy interventions warrant 
detailed assessment. For example, the present patient reporting feeling more energized is a 
 common response during treatment with IVABs, particularly electively. However, patients 
must often continue treatment until a change in lung function is observed. CPET may provide 
a more sensitive outcome measure to detect subtle changes earlier.   
 It is acknowledged that case study data are limited in its generalizability to the wider 
patient population. Furthermore, the follow-up time was relatively short and it would have 
been of interest to have performed CPET at week 20. In addition, no measurements of 
habitual physical activity were obtained to see whether improved exercise capacity translated 
into increased levels of physical activity.  
 Given the ongoing change in stance from the European Cystic Fibrosis Society 
regarding the clinical relevance of CPET in CF, it is likely that this will become a routine 
assessment method over the coming years. If more physical therapists involved in the 
management and treatment of this condition can adopt this form of testing, this would be of 
great benefit. It is hoped that this study demonstrates how insightful and relatively 
straightforward CPET is and will encourage more physical therapists to adopt it in clinical 
practice and as an investigative tool.  
 
CONCLUSION 
These cases demonstrate that not only does ivacaftor have a substantial beneficial effect on 
the sweat chloride of patients with CF and the G551D mutation, but clinically meaningful 
improvement in aerobic fitness can also be observed in the absence of exercise training. 
These changes manifest earlier than current clinical outcomes and result from both improved 
muscle O2 delivery and extraction during exercise. However, a fitness threshold may exist 
whereby patients who are relatively fit experience less or no improvement. Importantly, this 
case review highlights that CPET can provide an additional important clinical outcome 
measure to assess functional change and with this the mechanism(s) responsible for change. 
 CPET can detect substantial changes in aerobic fitness, which may occur independently from 
adaptations in pulmonary function, as was evidenced in 1 of the present patients. To 
objectively quantify the influence of pharmacological or physical therapy interventions on 
patients’ physiological function, the use of CPET is encouraged. CPET should be included 
within future, long-term research demonstrating its utility within physical therapy practice, 
pharmacological or exercise interventions.   
 
REFERENCES   
1. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell 
function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 
2009;106(44):18825-18830. 
2. Accurso FJ, Rowe SM, Clancy J, et al. Effect of VX-770 in persons with cystic 
fibrosis and the G551D-CFTR mutation.  N Engl J Med. 2010;363(21):1991-2003.  
3. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with 
cystic fibrosis and the G551D mutation. N Eng J Med. 2011;365(18):1663-1672. 
4. McKone E, Li H, Davies JC, on behalf of the VX08-770-105 Study Group. Long-
term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the 
G551D-CFTR mutation (abstract). J Cyst Fibros. 2012;11(Suppl.1):S13. 
5. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in 
patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir 
Crit Care Med. 2013;187(11):1219-1225. 
6. Hebestreit H, Sauer-Heilborn A, Fischer R, Käding M, Mainz JG. Effects of Ivacaftor 
on severely ill patients with cystic fibrosis carrying a G551D mutation. J Cystic 
Fibros. 2013;12(6):599-603. 
 7. Harrison MJ, Murphy DM, Plant BJ. Ivacaftor in a G551D homozygote with cystic 
fibrosis. New Eng. J. Med. 2013;369(13):1280-1282. 
8. Welsh MJ. Targeting the basic defect in cystic fibrosis. N Engl J Med. 
2010;363(21):2056-2057. 
9. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise 
testing in patients with cystic fibrosis. N Engl J Med. 1992;327(25):1785-1788.  
10. Pianosi P, Leblanc J, Almudevar A. Peak oxygen uptake and mortality in children 
with cystic fibrosis. Thorax. 2005;60(1):50-54. 
11. de Jong W, Kaptein AA, van der Schans CP, et al. Quality of life in patients with 
cystic fibrosis. Pediatr Pulmonol. 1997;23(2):95-100. 
12. Pérez M, Groeneveld IF, Santana-Sosa E, et al. Aerobic fitness is associated with 
lower risk of hospitalization in children with cystic fibrosis. Pediatr Pulmonol. 2013, 
doi: 10.1002/ppul.22878. [Epub ahead of print].  
13. Bell SC, Morris NR. Exercise testing in patients with cystic fibrosis: why and which? 
J Cyst Fibrosis. 2010;9(5):299-301. 
14. Whipp BJ, Davis JA, Torres F, Wasserman K. A test to determine parameters of 
aerobic function during exercise. J Appl Physiol, 1981;50(1):217-221. 
15. Saynor ZL, Barker AR, Oades PJ, Williams CA. A protocol to determine valid V̇O2max 
in young cystic fibrosis patients. J Sci Med Sport. 2013;16(6):539-544. 
16. Saynor ZL, Barker AR, Oades PJ, Williams CA. Reproducibility of maximal 
cardiopulmonary exercise testing for young cystic fibrosis patients. J Cystic Fibros. 
2013;12(6):644-650.  
17. Stanojevic S, Wade A, Cole TJ, Lum S, Custovic A, Silverman M, Hall GL, Welsh L, 
Kirkby J, Nystad W, Badier M, Davis S, Turner S, Piccioni P, Vilzni D, Eigen H, 
Vlachos-Mayer H, Zheng J, Tomalak W, Jones M, Hankinson JL, Stocks J; Asthma 
 UK Collaborative Group. Spirometry centile charts for young Caucasian children: the 
asthma UK collaborative initiative. Am J Respir Crit Care Med, 2009;180(6):547-
552. 
18. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic 
threshold by gas exchange. J Appl Physiol 1986;60(6):2020-2027. 
19. Pianosi PT. Impedance cardiography accurately measures cardiac output during 
exercise in children with cystic fibrosis. Chest. 1997;111(2):333-337.   
20. Hulzebos HJ, Sneider H, van der Net J, Helders PJM, Takken T. High-intensity 
interval training in an adolescent with cystic fibrosis: a physiological perspective. 
Physiother Theory Pract. 2011;27(3):231-237. 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE LEGENDS 
 
Figure 1. High-resolution computed tomography images for case A and case B pretreatment 
with orally administered ivacaftor. Case A microbiology: Mycobacterium abscessus, 
Stenotrophomas maltophilia, allergic bronchopulmonary aspergillosis in remission. Case B 
microbiology: Intermittent Pseudomonas Aeruginosa and previous Achromobacter 
xylosoxidans.  
 
Figure 2. Percentage change from baseline in body mass index, forced expiratory volume in 
1 second (percentage predicted
17
) and body mass normalized V̇O2max in 2 patients with cystic 
fibrosis patients (CF) with the G551D-CFTR mutation [A (14 y female; ● black circles) and 
B (16 y male; ○ white circles)] at the start of ivacaftor (day 0) and following 6, 12 and 20 
weeks of treatment. Exercise testing was not performed at 20 weeks and the magnitude of 
change is presented in relation to the typical error of measurements in young patients with CF 
over a 4- to 6-week period
16
.   
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Table 1. The clinical and exercise-based response of 2 pediatric cystic fibrosis patients (A, 14 
y female; B, 16 y male) with the ∆F508/G551D mutation to  6 and 12 weeks of oral ivacaftor 
treatment
a
.  
 
Variable Case A 
Pre-
Ivacaftor 
Case A 
6 weeks 
post 
Case A 
12 weeks 
post  
Case B 
Pre-
Ivacaftor 
Case B 
6 weeks 
post 
Case B 
12 weeks  
post 
Clinical outcomes - - - - - - 
FEV1 [L∙min
-1
 (%predicted)] 2.53 (92) 2.62 (96) 2.65 (97) 4.19 (108) 4.33 (112) 4.65 (120) 
FVC [L∙min-1 (%predicted)] 3.20 (100) 3.36 (105) 3.32 (107) 4.86 (104) 4.59 (98) 4.98 (106) 
FEF25-75 [L∙min
-1
 (%predicted)] 2.29 (66) 2.38 (67) 2.52 (71) 4.77 (106) 5.08 (113) 5.41 (120) 
Sweat chloride concentration 
(mmol∙L-1) 
104 
- 
21 
- 
35 
- 
107 
- 
58 
- 
43 
- 
Body mass (kg) 48.5 50.5 50.2 58.3 58.3 58.8 
Stature (cm) 154.8 155.0 155.0 172.0 172.0 172.2 
Maximal exercise parameters - - - - - - 
Absolute V̇O2max (L∙min
-1 
) 1.45  1.60  1.95 2.59  2.60 2.44 
Relative V̇O2max  
(mL∙kg-1∙min-1) 
29.42 
- 
31.30 
- 
38.33 
- 
44.20 
- 
45.72 
- 
41.93 
- 
HRmax (beats∙min
-1
) 205 202 202 198 195 175 
SVmax (mL) 52.4 56.2 60.3 83.9 89.2 104.2 
Q̇max (L∙min
-1
) 10.6 10.8 11.6 19.0 15.5 18.2 
a-V̇O2 diff. (mL∙min
-1∙100mL) 13.7 14.8 16.8 13.6 16.8 13.4 
Lowest SaO2 (%) 92 96 98 96 96 98 
RPE 10 9 9 9 9 9 
RPD 7 6 5 7 7 9 
Ramp peak power output (W) 136 129 148 220 225 240 
Submaximal parameters - - - - - -              
V̇O2 at the GET (L∙min
-1
) 0.87 0.85 0.87 1.32 1.28 1.09                                             
%GET (% of V̇O2max) 60.12 52.99 44.55 51.05 54.78 44.72                             
∆V̇O2/∆WR (mL·min
-1
·W
-1
)  7.20 8.00 7.40 9.32 8.46 6.52 
  
a
Values are means ± SD, with the range also displayed unless otherwise stated. Additional submaximal 
parameters are available upon request.  
Abbreviations: % predicted, percentage predicted
17
; C(a-v)O2., arterial-venous O2 content difference; ?̇?max, 
maximal cardiac output; V̇O2max, maximal oxygen uptake; ∆V̇O2/∆WR, oxygen cost of exercise (V̇O2 gain); 
FEF25-75, mid forced expiratory flow; FEV1, forced expiratory volume in 1 second; FVC, forced expiratory lung 
volume; GET, non-invasive estimate of the lactate threshold which was verified by the ventilatory threshold; 
HRmax, maximal heart rate; ramp; incremental ramp test; RPD, end-exercise rating of perceived dyspnea; RPE, 
end-exercise rating of perceived exertion; SpO2, arterial oxygen saturation; SVmax, maximal stroke volume; 
URTI, upper respiratory tract infection.  
 
 
 
 
 
